{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:23:15Z","timestamp":1786983795703,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier","isbn-type":[{"value":"9780323854825","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.podrm.2021.10.003","type":"book-chapter","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T03:06:24Z","timestamp":1649127984000},"page":"91-111","source":"Crossref","is-referenced-by-count":20,"title":["Ticagrelor"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.podrm.2021.10.003_bb0010","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40256-015-0108-5","article-title":"Ticagrelor: a review of its use in adults with acute coronary syndromes","volume":"15","author":"Dhillon","year":"2015","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"10","key":"10.1016\/bs.podrm.2021.10.003_bb0015","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/phar.1477","article-title":"Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety","volume":"13","author":"Dobesh","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/bs.podrm.2021.10.003_bb0020","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.clinthera.2012.04.005","article-title":"Ticagrelor: oral reversible P2Y 12 receptor antagonist for the management of acute coronary syndromes","volume":"34","author":"Cheng","year":"2012","journal-title":"Clin. Ther."},{"issue":"23","key":"10.1016\/bs.podrm.2021.10.003_bb0025","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/j.jacc.2014.03.031","article-title":"Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance","volume":"63","author":"Cattaneo","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/bs.podrm.2021.10.003_bb0030","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/0897190014568383","article-title":"Developments in oral antiplatelet agents for the treatment of acute coronary syndromes: clopidogrel, prasugrel, and ticagrelor","volume":"29","author":"Roffman","year":"2016","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/bs.podrm.2021.10.003_bb0035","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/11630960-000000000-00000","article-title":"Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor","volume":"51","author":"Teng","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/bs.podrm.2021.10.003_bb0040","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s40262-015-0290-2","article-title":"Ticagrelor: pharmacokinetic, pharmacodynamic and pharmacogenetic profile: an update","volume":"54","author":"Teng","year":"2015","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/bs.podrm.2021.10.003_bb0045","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3163\/1536-5050.100.1.018","article-title":"Martindale: the complete drug reference. 37th ed","volume":"100","author":"Wisher","year":"2012","journal-title":"J. Med. Libr. Assoc."},{"issue":"21","key":"10.1016\/bs.podrm.2021.10.003_bb0050","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1016\/j.bmcl.2007.07.057","article-title":"From ATP to AZD6140: the discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis","volume":"17","author":"Springthorpe","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/bs.podrm.2021.10.003_bb0055","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.molstruc.2018.05.056","article-title":"Acid-induced isomerization of ticagrelor: systematic exploration on reaction condition and mechanism","volume":"1170","author":"Bao","year":"2018","journal-title":"J. Mol. Struct."},{"key":"10.1016\/bs.podrm.2021.10.003_bb0060","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2147\/IJN.S190426","article-title":"Strategic approach to developing a self-microemulsifying drug delivery system to enhance antiplatelet activity and bioavailability of ticagrelor","volume":"14","author":"Na","year":"2019","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/bs.podrm.2021.10.003_bb0065","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejps.2017.06.031","article-title":"Investigating therapeutic usage of combined ticagrelor and aspirin through solid-state and analytical studies","volume":"107","author":"Sadou Yay\u00e9","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/bs.podrm.2021.10.003_bb0070","first-page":"1","article-title":"Fabrication and solid state characterization of ticagrelor co-crystals with improved solubility and dissolution","volume":"8","author":"Shane","year":"2017","journal-title":"Int. J. Pharm. Qual. Assur."},{"key":"10.1016\/bs.podrm.2021.10.003_bb0075","unstructured":"Article ID: 1118 Page 1 of 7 International Journal of Chemical & Pharmaceutical Analysis October\u2013December 2016, Int. J. Chem. Pharm. Anal., vol. 4, no. December, pp. 1\u20138, 2016."},{"issue":"3","key":"10.1016\/bs.podrm.2021.10.003_bb0080","doi-asserted-by":"crossref","first-page":"51","DOI":"10.22159\/ijap.2017v9i3.17452","article-title":"Bioanalytical method development and validation of ticagrelor by RP-HPLC","volume":"9","author":"D'Cruz","year":"2017","journal-title":"Int. J. Appl. Pharm."},{"issue":"9","key":"10.1016\/bs.podrm.2021.10.003_bb0085","first-page":"206","article-title":"Development and validation of RP- HPLC method for determination of ticagrelor in pharmaceutical dosage formulation","volume":"8","author":"Joshy","year":"2016","journal-title":"Pharm. Lett."},{"issue":"5","key":"10.1016\/bs.podrm.2021.10.003_bb0090","first-page":"268","article-title":"Analytical method development and validation for the estimation of ticagrelor in drug substance by RP-HPLC method","volume":"4","author":"Kapil","year":"2017","journal-title":"Eur. J. Biomed. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2021.10.003_bb0095","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejps.2018.03.029","article-title":"Application of quality by design to optimize a stability-indicating LC method for the determination of ticagrelor and its impurities","volume":"118","author":"Wingert","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/bs.podrm.2021.10.003_bb0100","first-page":"36","article-title":"Development of a validated HPLC-PDA method for stability indicating study of ticagrelor: a novel anti-platelet agent (P2Y 12-ADP receptor blocker)","volume":"7","author":"Sulthana","year":"2017","journal-title":"Int. J. Pharm. Chem. Biol. Sci."},{"issue":"4","key":"10.1016\/bs.podrm.2021.10.003_bb0105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2174\/1573412910666140610211656","article-title":"Determination of the new antiplatelet agent ticagrelor in tablets by stability-indicating HPLC method","volume":"10","author":"Gobetti","year":"2014","journal-title":"Curr. Pharm. Anal."},{"issue":"3","key":"10.1016\/bs.podrm.2021.10.003_bb0110","first-page":"634","article-title":"A validated stability-indicating HPLC method for determination of ticagrelor in bulk and its formulation","volume":"3","author":"Kalyani","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/bs.podrm.2021.10.003_bb0115","first-page":"94","article-title":"RP-HPLC and UV spectrophotometric methods for estimation of ticagrelor in pharmaceutical formulations","volume":"7","author":"Narware","year":"2018","journal-title":"Asian J. Pharm. Educ. Res."},{"issue":"8","key":"10.1016\/bs.podrm.2021.10.003_bb0120","first-page":"243","article-title":"Analysis of three cardiovascular drugs in their ternary mixture using green analytical methodology of smart spectrophotometric methods and RP-HPLC method","volume":"8","author":"Gazy","year":"2016","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"10.1016\/bs.podrm.2021.10.003_bb0125","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejps.2016.11.004","article-title":"HPLC method for simultaneous analysis of ticagrelor and its organic impurities and identification of two major photodegradation products","volume":"97","author":"Bueno","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"2","key":"10.1016\/bs.podrm.2021.10.003_bb0130","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3390\/molecules26020278","article-title":"Validation of an HPLC-MS\/MS method for the determination of plasma ticagrelor and its active metabolite useful for research and clinical practice","volume":"26","author":"Lagoutte-Renosi","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/bs.podrm.2021.10.003_bb0135","unstructured":"Food and Drug Administration (FDA), \u201cDepartment of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM) Guidance for Industry,\u201d Bioanal. Method Valid, 2018."},{"key":"10.1016\/bs.podrm.2021.10.003_bb0140","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchromb.2018.12.018","article-title":"Development of an LC-MS\/MS method for simultaneous determination of ticagrelor and its active metabolite during concomitant treatment with atorvastatin","volume":"1105","author":"Danielak","year":"2019","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.podrm.2021.10.003_bb0145","author":"Chae"},{"issue":"6","key":"10.1016\/bs.podrm.2021.10.003_bb0150","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/jat\/bkw039","article-title":"Simultaneous determination of ticagrelor and its metabolites in human plasma and urine using liquid chromatography-tandem mass spectrometry","volume":"40","author":"Zhong","year":"2016","journal-title":"J. Anal. Toxicol."},{"issue":"25","key":"10.1016\/bs.podrm.2021.10.003_bb0155","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.jchromb.2010.06.018","article-title":"Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry","volume":"878","author":"Sill\u00e9n","year":"2010","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/bs.podrm.2021.10.003_bb0160","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jpba.2014.11.046","article-title":"Identification of the major degradation pathways of ticagrelor","volume":"105","author":"Hassane","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/bs.podrm.2021.10.003_bb0165","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jpba.2015.12.037","article-title":"Four process-related potential new impurities in ticagrelor: identification, isolation, characterization using HPLC, LC\/ESI-MS(n), NMR and their synthesis","volume":"120","author":"Kumar","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"6","key":"10.1016\/bs.podrm.2021.10.003_bb0170","first-page":"538","article-title":"Assaying the antiplatelet ticagrelor by validated UV spectrophotometric method with performance equivalent to HPLC","volume":"13","author":"Oliveira","year":"2016","journal-title":"Curr. Pharm. Anal."},{"issue":"81","key":"10.1016\/bs.podrm.2021.10.003_bb0175","first-page":"316","article-title":"UV-vis spectrophotometric assay determination of oral antiplatelet ticagrelor drug in pharmaceutical formulation: application to content uniformity","volume":"2016","author":"Pandya","year":"2016","journal-title":"J. Chem. Pharm. Res."},{"issue":"19","key":"10.1016\/bs.podrm.2021.10.003_bb0180","first-page":"309","article-title":"A validated stability indicating method of UV-spectrophotometry for the estimation of ticagrelor in bulk & marketed formulation","volume":"8","author":"Anil Kumar","year":"2016","journal-title":"Pharm. Lett."},{"issue":"5","key":"10.1016\/bs.podrm.2021.10.003_bb0185","first-page":"172","article-title":"Spectrophotometric methods for determination of ticagrelor in dosage forms","volume":"3","author":"Souri","year":"2017"},{"key":"10.1016\/bs.podrm.2021.10.003_bb0190","doi-asserted-by":"crossref","first-page":"118722","DOI":"10.1016\/j.saa.2020.118722","article-title":"Rapid fluorometric determination of ticagrelor in tablets and rat plasma: application to pharmacokinetics study","volume":"242","author":"Elmansi","year":"2020","journal-title":"Spectrochim. Acta - Part A Mol. Biomol. Spectrosc."},{"issue":"12","key":"10.1016\/bs.podrm.2021.10.003_bb0195","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1149\/2.0361712jes","article-title":"Highly sensitive carbon based sensing utilizing titanium dioxide nanoparticles and multiwalled carbon nanotubes for determination of ticagrelor: pharmacokinetics application","volume":"164","author":"Rizk","year":"2017","journal-title":"J. Electrochem. Soc."},{"key":"10.1016\/bs.podrm.2021.10.003_bb0200","author":"El-Desoky"}],"container-title":["Profiles of Drug Substances, Excipients and Related Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512521000157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512521000157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T23:44:02Z","timestamp":1762559042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871512521000157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323854825"],"references-count":39,"URL":"https:\/\/doi.org\/10.1016\/bs.podrm.2021.10.003","relation":{},"ISSN":["1871-5125"],"issn-type":[{"value":"1871-5125","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}